JP2012502909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502909A5 JP2012502909A5 JP2011526923A JP2011526923A JP2012502909A5 JP 2012502909 A5 JP2012502909 A5 JP 2012502909A5 JP 2011526923 A JP2011526923 A JP 2011526923A JP 2011526923 A JP2011526923 A JP 2011526923A JP 2012502909 A5 JP2012502909 A5 JP 2012502909A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cluster headache
- pharmaceutically acceptable
- acceptable salt
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 208000006561 Cluster Headache Diseases 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 14
- 208000018912 cluster headache syndrome Diseases 0.000 claims 11
- VKRAXSZEDRWLAG-SJKOYZFVSA-N 2-bromo-lsd Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=C(Br)NC3=C1 VKRAXSZEDRWLAG-SJKOYZFVSA-N 0.000 claims 10
- 239000002552 dosage form Substances 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 4
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 claims 4
- 230000000306 recurrent effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 2
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229960001078 lithium Drugs 0.000 claims 1
- 229960001186 methysergide Drugs 0.000 claims 1
- 238000009117 preventive therapy Methods 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9777308P | 2008-09-17 | 2008-09-17 | |
| US61/097,773 | 2008-09-17 | ||
| PCT/US2009/055971 WO2010033392A2 (en) | 2008-09-17 | 2009-09-04 | Methods and kits for treating cluster headache disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502909A JP2012502909A (ja) | 2012-02-02 |
| JP2012502909A5 true JP2012502909A5 (enExample) | 2012-10-04 |
| JP5690732B2 JP5690732B2 (ja) | 2015-03-25 |
Family
ID=42040074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011526923A Active JP5690732B2 (ja) | 2008-09-17 | 2009-09-04 | 群発頭痛障害を治療するための方法及びキット |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8415371B2 (enExample) |
| EP (1) | EP2331100B1 (enExample) |
| JP (1) | JP5690732B2 (enExample) |
| CN (1) | CN102164603B (enExample) |
| BR (1) | BRPI0918623A2 (enExample) |
| CA (1) | CA2737135C (enExample) |
| GB (1) | GB2475660B (enExample) |
| IL (1) | IL211714A (enExample) |
| MX (1) | MX2011002883A (enExample) |
| WO (1) | WO2010033392A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859579B2 (en) * | 2008-03-21 | 2014-10-14 | Richard Andrew Sewell | Compostions and methods for preventing and/or treating disorders associated with cephalic pain |
| JP5690732B2 (ja) * | 2008-09-17 | 2015-03-25 | ザ マクリーン ホスピタル コーポレーション | 群発頭痛障害を治療するための方法及びキット |
| CA3132731A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| WO2021195427A1 (en) * | 2020-03-25 | 2021-09-30 | Ch Tac, Llc | 2-bromo-lysergic acid diethylamide for substance abuse |
| US20240058326A1 (en) * | 2020-12-22 | 2024-02-22 | Betterlife Pharma Inc. | Methods of treating mental or mood disorders using 2-bromo-lsd |
| US20240180894A1 (en) * | 2021-03-22 | 2024-06-06 | Betterlife Pharma Inc. | Methods of treating mental and/or mood disorders using 2-bromo-lsd alone or in combination with a mtor inhibitor |
| EP4329759A4 (en) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| JP7846211B2 (ja) * | 2021-08-19 | 2026-04-14 | デフィニウム セラピューティクス ユーエス， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 |
| KR20240088949A (ko) | 2021-09-20 | 2024-06-20 | 비라이프 테라퓨틱스 인크. | 질병 및 질환의 치료를 위한 lsd 유도체, 합성 및 방법 |
| EP4642780A2 (en) | 2022-12-31 | 2025-11-05 | Ceruvia Lifesciences LLC | Process for synthesizing 2-bromolysergic acid diethylamide via controlled hydrolysis of bromocriptine |
| WO2024145546A1 (en) | 2022-12-31 | 2024-07-04 | Ceruvia Lifesciences Llc | Process for synthesizing 2-bromolysergic acid diethylamide via controlled bromination of lysergic acid |
| US20240239789A1 (en) | 2022-12-31 | 2024-07-18 | Ceruvia Lifesciences Llc | Salts of 2-bromolysergic acid diethylamide |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3228959A (en) * | 1962-01-16 | 1966-01-11 | Geigy Chem Corp | Quaternary salts of certain indolealkylamines and therapeutic uses thereof |
| US4524072A (en) | 1984-06-18 | 1985-06-18 | Zivin Justin A | Reduction of stroke damage |
| DE3785507T2 (de) * | 1986-07-31 | 1993-07-29 | Beecham Group Plc | Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung. |
| GB8618700D0 (en) * | 1986-07-31 | 1986-09-10 | Beecham Group Plc | Compounds |
| RU2004126093A (ru) * | 2002-02-26 | 2005-04-10 | Орто-Макнейл Фармасьютикал, Инк. (Us) | Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени |
| US20070065463A1 (en) | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| US8859579B2 (en) * | 2008-03-21 | 2014-10-14 | Richard Andrew Sewell | Compostions and methods for preventing and/or treating disorders associated with cephalic pain |
| JP5690732B2 (ja) * | 2008-09-17 | 2015-03-25 | ザ マクリーン ホスピタル コーポレーション | 群発頭痛障害を治療するための方法及びキット |
-
2009
- 2009-09-04 JP JP2011526923A patent/JP5690732B2/ja active Active
- 2009-09-04 BR BRPI0918623A patent/BRPI0918623A2/pt not_active Application Discontinuation
- 2009-09-04 CN CN200980136477.XA patent/CN102164603B/zh not_active Expired - Fee Related
- 2009-09-04 CA CA2737135A patent/CA2737135C/en active Active
- 2009-09-04 MX MX2011002883A patent/MX2011002883A/es not_active Application Discontinuation
- 2009-09-04 US US12/935,737 patent/US8415371B2/en active Active
- 2009-09-04 EP EP09814995.8A patent/EP2331100B1/en active Active
- 2009-09-04 GB GB1104907.9A patent/GB2475660B/en not_active Expired - Fee Related
- 2009-09-04 WO PCT/US2009/055971 patent/WO2010033392A2/en not_active Ceased
-
2011
- 2011-03-14 IL IL211714A patent/IL211714A/en active IP Right Grant
-
2013
- 2013-03-12 US US13/796,618 patent/US20130252996A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502909A5 (enExample) | ||
| JP2013505205A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| JP2015515475A5 (enExample) | ||
| EA031157B9 (ru) | Вводимая перорально кортикостероидная композиция | |
| JP2012193216A5 (enExample) | ||
| WO2007081975A3 (en) | Method of treating multiple sclerosis | |
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2016540738A5 (enExample) | ||
| FI4321157T3 (fi) | Angiotensiinireseptorin salpaajan (arb) ja neutraalin endopeptidaasin estäjän (nepi) yhdistelmän uusi käyttötapa | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2010522137A5 (enExample) | ||
| JP2012502047A5 (enExample) | ||
| IL278188B2 (en) | Sublingual formulation of riluzole | |
| JP2016530291A5 (enExample) | ||
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| JP2011511006A5 (ja) | 肺病態に対する医薬組成物 | |
| JP2016512817A5 (enExample) | ||
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir |